|
Wednesday, 29 March 2006 Appointment of Governor creates board vacancy at MSHL Professor Williams is the Director of the Monash Institute of Medical Research in Melbourne, Australia succeeding Professor de Kretser. Prior to his appointments to the Monash Institute, New Zealand born Professor Williams enjoyed a distinguished international career as a cancer researcher in the basic and preclinical area. Positions held in recent years included a professorial chair at Case Western Reserve University, Cleveland, Ohio and adjunct professorships at Cleveland State University, and at Kent State University also both in Ohio, USA. Immediately before coming to Melbourne, Professor Williams was Chairman of the Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio, one of the leading cancer clinics in the US. Welcoming Professor Williams to the board, Marshall Edwards Chief Executive Officer, Mr Christopher Naughton, said his particular expertise and experience would assist with progressing the development of phenoxodiol, Marshall Edwards lead anti-cancer compound. Professor Williams joins the MEI board of directors which includes Professor Graham Kelly (Chairman), Mr Naughton (CEO), Professor Paul Nestel AO, and Messrs Philip Johnston and Stephen Breckenridge. Directors of Marshall Edwards congratulated Professor de Kretser on his appointment as Governor and wished him well in his position which they said was public recognition of his judgment, his illustrious career, his active and ongoing management and involvement in medical research and his advocacy across a broad range of biotechnology. Incorporated in the US State of Delaware, Marshall Edwards Inc. is 87 percent owned by ASX and NASDAQ listed pharmaceutical company, Novogen Limited from which it licences phenoxodiol, and its shares are traded in the US on NASDAQ (Code: MSHL). More information on phenoxodiol and on the company can be found at www.marshalledwardsInc com and www.novogen.com
|